Heterogeneity of chemosensitivity of metastatic cutaneous melanoma

Anti-Cancer Drugs

Volumn 10, Issue 5, 1999, Pages 437-444

  Cree, Ian A ^a   Neale, Michael H ^a   Myatt, Nyree E ^a   De Takats, Pippa G ^b   Hall, Per ^b   Grant, John ^b   Kurbacher, Christian M ^c   Reinhold, Uwe ^d   Neuber, Karsten ^e   MacKie, Rona M ^f   Chana, Jagdeep ^g   Weaver, Paul C ^h   Khoury, Ghassan G ^h   Sartori, Christian ⁱ   Andreotti, Peter E ^j  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f WESTERN INFIRMARY   (United Kingdom)

^g MOUNT VERNON HOSPITAL   (United Kingdom)

^h ST MARY S HOSPITAL   (United Kingdom)

ⁱ DCS Innovative Diagnostik Systeme   (Germany)

^j Atlantic Scientific Development Inc   (United States)

more..

Author keywords

Chemosensitivity; Luciferase; Melanoma

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA2B INTERFERON; CARMUSTINE; CISPLATIN; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; FOTEMUSTINE; GEMCITABINE; MITOXANTRONE; PACLITAXEL; TEMOZOLOMIDE; TREOSULFAN; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOSENSITIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; SKIN METASTASIS; TREATMENT PLANNING; DRUG RESPONSE; MELANOMA CELL;

EID: 0033410243     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199906000-00002     Document Type: Article

References (37)

1. Lee SM, Betticher DC, Thatcher N. Melanoma: chemotherapy. Br Med Bull 1995; 51: 609-30.
2. Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 1997; 9: 205-13.
3. Kirkwood JM, Strawderman MH, Enrstoff MS, Smith TJ, Borden EC, Blum RH. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
4. Bellamy WT. Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs 1992; 44: 690-708.
5. Bosanquet AG. In vitro drug sensitivity testing for the individual patient: an ideal adjunct to current methods of treatment choice. Clin Oncol 1993; 5: 195-7.
6. Cree IA, Kurbacher CM. Individualizing chemotherapy for solid tumors - is there any alternative? Anti-Cancer Drugs 1997; 8: 541-8.
7. Andreotti PE, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276-82.
8. Cree IA, Kurbacher CM, Untch M, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs 1996; 7: 630-5.
9. Kurbacher CM, Cree IA, Bruckner HW, Mallman P, Andreotti PE. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anti-Cancer Drugs 1998; 9: 51-7.
10. Myatt N, Cree JA, Kurbacher CM, Foss AJE, Hungerford JL, Plowman PN. The ex vivo chemosensitivity profile of choroidal melanoma. Anti-Cancer Drugs 1997; 8: 756-62.
11. Neale MH, Myatt N, Cree IA, et al. Combination chemotherapy for chroroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 1999; 79: 1487-93.
12. Kurbacher CM, Untch M, Cree IA. A randomised trial of chemotherapy directed by a tumour chemosensitivity assay versus physician's choice in patients with recurrent platinum-resistant ovarian adenocarcinoma. Lancet Internet publicatlon 1997: http://www.thelancet.com/newlancet/sub/author//menu_NOD7.html
13. Hunter EM, Sutherland LA, Cree IA, et al. The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity, assay. Anti-Cancer Drugs 1994; 5: 171-6.
14. Schadendoff D, Jurgovsky K, Worm M, Czarnetzki BM., In vitro sensitivity of human melanoma cells to chemotherapeutic agents and interferons. Melanoma Res 1994; 4: 243-9.
15. Tachihara R. The effect of dacarbazine and vincristine sulfate on human melanoma cell lines. In vitro analysis of interaction on DNA synthesis, RNA synthesis and protein synthesis. Nippon Ika Daigaku Zasshi 1997; 64: 238-48 (abstr).
16. Marshall ES, Finlay GJ, Matthews JH, Shaw JH, Nixon J, Baguley BC. Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst 1992; 84: 340-5.
17. Schadendorf D, Worm M, Algermissen B, Kohlmus CM, Czarnetzki BM. Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity. Cancer 1994; 73: 103-8.
18. Muhonen T, Pyrhönen S, Laasonen A, et al. Mouse subrenal capsule assay chemosensitivity and DNA flow cytometry, parameters of human melanoma metastases. Acta Oncol 1994; 33: 431-7.
19. Hahka-Kemppinen M, Muhonen T, Kangas L, Pyrhönen S. Chemosensitivity of human melanoma metastases in mouse subrenal capsule assay - can it predict tumour response to combined cystostatic plus interferon therapy in metastatic melanoma? Melanoma Res 1996; 6: 215-21.
20. Metelmann HR, Von Hoff DD. In vitro activation of dacarbazine (DTIC) Ibr a human tumor cloning system. Int J Cell Cloning 1983; 1: 24-32.
21. Raymond E, Izbicka E, Soda H, Gerson S, Dungan M, Von Hoff DD, Effects of temozolomide against human tumor using the human tumor cloning assay. Ann Oncol 1998; 9 (suppl 2): 38.
22. Neuber K, tom Dieck A, Bloedorn-Schlicht N, Itschert G, Karnback C. Treosulfan is an effective alkylating cytostatic for malignant melenoma in vitro and in vivo. Melanoma Res 1999; 9: 125-32.
23. Hartley JA, O'Hare CC, Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer 1998; 79: 264-6.
24. Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res 1998; 8: 17-23.
25. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5: 1232-9.
26. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer 1990; 65: 2478-81.
27. Wiernik PH, Einzig AL. Taxol in malignant melanoma. J Natl Cancer Inst Monogr 1993; 15: 185-7.
28. Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 1995; 13: 2895-9.
29. Einzig AI, Schuchter LM, Recio A, Coatsworth S, Rodriquez R, Wiernik PH Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med Oncol 1996; 13: 111-7.
30. Berger W, Hauptmann E, Elbling I., Vetterlein M, Kokoschka EM, Micksche M. Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. Int J Cancer 1997; 71: 108-15.
31. Schadendorf D, Makki A, Stahr C, et al. Membrane transport proteins associated with drug resistance ex pressed in human melanoma. Am J Pathol 1995; 147: 1545-52.
32. Mohith A, Photiou A, Retsas S. The combination of paclitaxel with cisplatin exhibits antagonism in vitro against human melanoma. Anti-Cancer Drugs 1996; 7: 493-8.
33. Tveit KM, Fodstad O, Pihl A. The usefulness of human tumor cell lines in the study of chemosensitivity. A study of malignant melanomas. Int J Cancer 1981; 28: 403-8.
34. Andreotti PE, Linder D, Hartmann DM, Cree IA, Pazzagli M, Bruckner HW. TCA-100 tumor chemosensitivity assay: differences in sensitiviity between cultured tumor cell lines and clinical studies. J Biolumin Chemilumin 1994; 9: 373-8.
35. Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 30A: 1061-4.
36. Retsas S, Mohith A, Mackenzie H. Taxol and vinorelbine: a new active combination for disseminated malignant melanoma. Anti-Cancer Drugs 1996; 7: 161-5.
37. Photiou A, Shah P, Leong LK, Moss J, Retsas S. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer 1997; 33: 463-70.